Table 2. Plasma fibrin clot characteristics, thrombin generation parameters, and fibrinolysis activators and inhibitors assessed in peripheral blood before, during, and after the LAAO procedure as well as in the left atrial appendage in patients undergoing the LAAO.

Variable	Peripheral blood before LAAO (a)	LAA	Peripheral blood after LAAO (b)	P value (a vs. b)	Peripheral blood after 1-month follow-up (c)	P value (a vs. c)	Normal values (n=20)
Fibrinogen, g/L	2.23 [1.75–2.72]	2.42 [2.15–2.65]	4.17 [3.69–4.86]	0.0051	2.31 [2.06–2.63]	0.028	2.49 [2.02–3.12]
ETP, nM × min	1,480 [1,263–1,649]	1,572 [1,238–2,122]	1,791 [1,547–2,214]	0.043	1,389 [1,273–1,460]	0.69	1,207 [964–1,321]
Peak thrombin, nM	215 [169–262]	212 [152–273]	243 [186–295]	0.22	189 [146–256]	0.50	173 [149–195]
tPA antigen, ng/mL	9.48 [5.06–11.54]	9.78 [4.32–12.02]	9.50 [8.12–13.05]	0.53	5.42 [3.43–7.46]	0.15	6.67 [5.09–10.6]
PAI-1 antigen, ng/mL	4.29 [1.76–6.44]	3.82 [1.89–5.04]	3.76 [2.83–4.39]	0.81	2.06 [0.97–2.74]	0.023	5.09 [2.31–8.45]
TAFI antigen, %	81.0 [63.8–91.2]	84.2 [67.3–95.1]	100.1 [90.4–106.1]	0.034	88.3 [75.6–99.5]	0.075	87.7 [81.6–91.5]
Plasminogen, %	90.6 [85.5–98.1]	81.5 [70.6–89.4]	101.3 [84.7–112.4]	0.021	98.7 [91.2–113.4]	0.0077	100.3 [93.2–104.1]

Data are presented as median [Q1–Q3] and were compared using the Wilcoxon signed-rank test. LAAO, left atrial appendage occlusion; LAA, left atrial appendage; ETP, endogenous thrombin potential; tPA antigen, tissue plasminogen activator antigen; PAI-1 antigen, plasminogen activator inhibitor type 1 antigen; TAFI antigen, thrombin activatable fibrinolysis inhibitor antigen.